Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia

References

• Centers for Disease Control and Prevention. Viral hepatitis surveillance: estimates of disease burden from viral hepatitis. Available at: http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm. Accessed October 20, 2010
   Google Scholar
• Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ 2008;57:1-24
   PubMedGoogle Scholar
• Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62
   PubMed Web of Science ®Google Scholar
• Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National hepatitis C prevention strategy. Summer; 2001: http://www.cdc.gov/hepatitis/hcv/Strategy/PDFs/NatHepCPrevStrategy.pdf. Accessed November 8, 2010
   Google Scholar
• Centers for Disease Control and Prevention. Hepatitis C: fact sheet. June 2010: http://www.cdc.gov/hepatitis/hcv/pdfs/hepcgeneralfactsheet.pdf. Accessed November 8, 2010
   Google Scholar
• Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26(3 Suppl 1):15-20S
   Google Scholar
• Xu J, Kochanek KD, Murphy SL, et al. Deaths: final data for 2007. Natl Vital Stat Rep 2010;58:1-135
   PubMedGoogle Scholar
• Shiffman ML, Saab S, Feng S, et al. Liver and intestine transplantation in the United States, 1995-2004. Am J Transplant 2006;6:1170-87
   PubMed Web of Science ®Google Scholar
• Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000;95:2936-9
   PubMed Web of Science ®Google Scholar
• Bordin G, Ballare M, Zigrossi P, et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol 1995;13(Suppl 13):S39-43
   Google Scholar
• Wang CS, Yao WJ, Wang ST, et al. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection. Clin Infect Dis 2004;39:790-6
   PubMed Web of Science ®Google Scholar
• Giannini E, Borro P, Botta F, et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol 2002;37:572-7
   PubMed Web of Science ®Google Scholar
• Nagamine T, Ohtuka T, Takehara K, et al. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996;24:135-40
   PubMed Web of Science ®Google Scholar
• Sharma P, McDonald GB, Banaji M. The risk of bleeding after percutaneous liver biopsy: relation to platelet count. J Clin Gastroenterol 1982;4:451-3
   PubMed Web of Science ®Google Scholar
• Liangpunsakul S, Ulmer BJ, Chalasani N. Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sci 2003;326:111-16
   PubMed Web of Science ®Google Scholar
• McVay PA, Toy PT. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol 1990;94:747-53
   PubMed Web of Science ®Google Scholar
• Williford SK, Salisbury PL 3rd, Peacock JE Jr., et al. The safety of dental extractions in patients with hematologic malignancies. J Clin Oncol 1989;7:798-802
   PubMedGoogle Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
   PubMed Web of Science ®Google Scholar
• Shimakami T, Lanford RE, Lemon SM. Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities. Curr Opin Pharmacol 2009;9:537-44
   PubMed Web of Science ®Google Scholar
• Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med 2004;71(Suppl 3):S17-21
   Google Scholar
• Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71
   PubMed Web of Science ®Google Scholar
• Poordad F. Thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther. 2007;26(Suppl 1):5-11
   Google Scholar
• Weksler BB. The pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther 2007;26(Suppl 1):13-19
   Google Scholar
• Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep [May 2; 2001:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9790221. Accessed April 29, 2008
   Google Scholar
• Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003;37:533-41
   PubMedGoogle Scholar
• McCullough J. Current issues with platelet transfusion in patients with cancer. Semin Hematol 2000;37(2 Suppl 4):3-10
   Google Scholar
• Rinder HM, Arbini AA, Snyder EL. Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol 1999;6:437-41
   PubMedGoogle Scholar
• McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007;132:103-12
   PubMed Web of Science ®Google Scholar
• Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-64; quiz 214-37
   PubMed Web of Science ®Google Scholar
• Brown Jr RS. A pharmacoeconomic analysis of thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther 2007;26(Suppl 1):41-8
   Google Scholar
• Pegasys® (peginterferon alfa-2a). Full prescribing information. Hoffmann-La Roche Inc. Nutley, NJ, 2008
   Google Scholar
• PegIntron® (peginterferon alfa-2b). Full prescribing information. Schering-Plough Corporation. Kenilworth, NJ, 2009
   Google Scholar
• Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-14
   PubMed Web of Science ®Google Scholar
• Wasley A, Miller JT, Finelli L. Surveillance for acute viral hepatitis—United States, 2005. MMWR Surveill 2007;56:1-24
   PubMedGoogle Scholar